Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study

Lyn D. Ferguson 1, Jennifer Linge2,3, Olof Dahlqvist Leinhard2,3, Rosemary Woodward4, Pauline Hall Barrientos4, Giles Roditi4, Aleksandra Radjenovic1, Iain B. McInnes5, Stefan Siebert5 and Naveed Sattar1

Abstract

Objectives. To compare body composition in PsA with metabolic disease free (MDF) controls and type 2 diabetes and assess body-composition predicted propensity for cardiometabolic disease.

Methods. Detailed MRI body composition profiles of 26 PsA participants from the IMAPA study were compared with 130 age, sex and BMI-matched MDF controls and 454 individuals with type 2 diabetes from UK Biobank. The body-composition predicted propensity for coronary heart disease (CHD) and type 2 diabetes was compared between PsA and matched MDF controls.

Results. PsA participants had a significantly greater visceral adipose tissue (VAT) volume [mean 5.89 l (s.d. 2.10 l)] compared with matched-MDF controls [mean 4.34 l (S.D. 1.83 l)] (P < 0.001) and liver fat percentage [median 8.88% (inter-quartile range 4.42–13.18%)] compared with MDF controls [3.29% (1.98–7.25%)] (P < 0.001). These differences remained significant after adjustment for age, sex and BMI. There were no statistically significant differences in VAT, liver fat or muscle fat infiltration (MFI) between PsA and type 2 diabetes. PsA participants had a lower thigh muscle volume than MDF controls and those with type 2 diabetes. Body composition-predicted propensity for CHD and type 2 diabetes was 1.27 and 1.83 times higher, respectively, for PsA compared with matched-MDF controls.

Conclusion. Individuals with PsA have an adverse body composition phenotype with greater visceral and ectopic liver fat and lower thigh muscle volume than matched MDF controls. Body fat distribution in PsA is more in keeping with the pattern observed in type 2 diabetes and is associated with greater propensity to cardiometabolic disease. These data support the need for greater emphasis on weight loss in PsA management to lessen CHD and type 2 diabetes risk.

Key words: psoriatic arthritis, ectopic fat, obesity, diabetes, CHD

Introduction

Increased BMI is strongly associated with PsA [1]. However, BMI is a global adiposity marker, and does not capture regional fat. Central obesity, assessed increased waist circumference, is independently associated with higher odds of psoriasis [2]. The site of fat storage is important as visceral adipose tissue (VAT) and ectopic fat including fat in the liver and skeletal muscle are associated with increased metabolic risk [3, 4]. Body composition profiling with MRI allows detailed assessment of body fat distribution including quantification of abdominal subcutaneous adipose tissue (ASAT), VAT, ectopic fat including liver fat and muscle fat infiltration (MFI), as well as fat-free thigh muscle volume (FFMV). Higher VAT and FFI have been associated with greater coronary heart disease (CHD) and type 2 diabetes prevalence, and higher liver fat with type 2 diabetes, independently of BMI [5]. Greater MFI and lower FFMV may assist in the diagnosis of sarcopenia [6], for which there are currently few data available in PsA.
We aimed to characterize for the first time the detailed body composition profile of PsA using MRI compared with age, sex and BMI-matched metabolic disease free (MDF) controls and type 2 diabetes, and to relate body composition to propensity for CHD and type 2 diabetes in PsA vs MDF controls.

Methods

Study design and participants

PsA participants were recruited from the Immune Metabolic Associations in PsA (IMAPA) study. This open label mechanistic study investigated cardiometabolic outcomes in psoriatic disease treated with apremilast [7]. PsA participants were required to fulfill the Classification for PsA (CASPAR) criteria [8] and Scottish Medicines Consortium guidelines for apremilast [9]. Exclusion criteria included other autoimmune rheumatic diseases, severe renal disease, transaminitis > four times upper limit of normal, significant recent weight loss, pregnancy, insulin-dependent diabetes, and biologic/leflunomide treatment. Between June 2017 and November 2019, 29 PsA participants underwent body composition profiling with a 3.0-T MRI scanner (Prisma, Siemens, Erlangen, Germany) at baseline prior to starting apremilast. After excluding three participants with type 2 diabetes, body composition data from 26 PsA participants were compared with 130 age, sex and BMI-matched MDF controls from UK Biobank [10], a large, general population-based cohort of 502,682 participants aged 40–70 years, which included MR imaging of 10,000 participants. PsA participants were recruited from the Immune Medicines Consortium guidelines for apremilast [9]. All participants underwent standardized imaging protocols with analyses read in a blinded fashion. Between MR scanner bias and reproducibility coefficients have been recently published by AMRA Medical AB, Linkoping, Sweden [11]. The propensity for CHD or type 2 diabetes based on body composition was calculated according to the method described by Linge et al. [12]. For each PsA participant, the propensity for these conditions was estimated by the prevalence of CHD and type 2 diabetes within personalized control groups from UK Biobank matched for sex and body fat distribution (VAT index, ASAT index, liver fat and MFI) by applying the adaptive k-nearest neighbors algorithm.

Statistical analysis

All analyses were performed using R version 3.4.4 (The R Foundation, Vienna, Austria). Continuous data presented as mean (S.D.), except liver fat presented as median and interquartile range (IQR); categorical data presented as number (n) and percentage (%). Body composition in PsA was compared with age, sex and BMI-matched MDF controls using mixed effects linear regression and to type 2 diabetes using linear regression. Analyses were further adjusted for age, sex and BMI. The difference in distributions of variables used for matching (age and BMI) between PsA and matched MDF controls were tested using Wilcoxon signed-rank test. Body-composition predicted CHD and type 2 diabetes propensities were compared between PsA and MDF controls using Wilcoxon signed-rank test.

The IMAPA study received ethical approval from West of Scotland Research Ethics Committee 4 (Reference 17/WS/0006). The UK Biobank study was approved by
**Table 1** Comparison of body composition parameters between PsA, matched metabolic disease free (MDF) controls, and type 2 diabetes

| Variable                        | PsA (n = 26) | MDF controls (n = 130) | P-valuea | Adj. P valueb | Type 2 diabetes (n = 454) | P-valuec | Adj. P valued |
|--------------------------------|--------------|------------------------|----------|---------------|--------------------------|----------|---------------|
| Age (years)                    | 56.0 (9.0)   | 57.4 (6.5)             | 0.766    | —             | 65.4 (6.9)               | < 0.001  | —             |
| Female (n, %)                  | 13 (50)      | 65 (50)                | 1.000    | —             | 158 (34.8)               | < 0.001  | —             |
| BMI (kg/m²)                    | 31.2 (6.4)   | 30.5 (5.3)             | 0.799    | —             | 29.9 (5.2)               | 0.397    | —             |
| VAT (l)                        | 5.89 (2.10)  | 4.34 (1.83)            | < 0.001  | < 0.001       | 5.93 (2.56)              | 0.937    | 0.434         |
| Visceral fat index (l/m²)      | 2.06 (0.73)  | 1.52 (0.64)            | < 0.001  | < 0.001       | 2.03 (0.84)              | 0.842    | 0.243         |
| ASAT (l)                       | 10.48 (4.90) | 9.42 (4.86)            | 0.002    | 0.063         | 8.58 (3.93)              | 0.019    | 0.318         |
| Abdominal fat index (l/m²)     | 5.87 (2.39)  | 4.93 (2.29)            | < 0.001  | < 0.001       | 5.04 (1.92)              | 0.036    | 0.017         |
| Liver fat (%)                  | 8.88 (4.42–13.18) | 3.29 (1.98–7.25) | < 0.001  | < 0.001       | 6.13 (2.77–11.63)        | 0.160    | 0.999         |
| MFI (%)                        | 7.74 (2.57)  | 7.43 (1.95)            | 0.316    | 0.283         | 8.61 (2.29)              | 0.062    | 0.165         |
| FFMV, l                        | 10.40 (2.38) | 11.43 (2.88)           | 0.001    | < 0.001       | 11.1 (2.34)              | 0.142    | 0.002         |
| FFMV VCG, S.D. VCG            | -0.74 (1.71) | 0.40 (1.14)            | < 0.001  | < 0.001       | -0.31 (1.03)             | 0.052    | < 0.001       |
| WMR (kg/l)                     | 8.89 (1.95)  | 7.96 (1.99)            | < 0.001  | < 0.001       | 8.03 (1.52)              | 0.006    | < 0.001       |

Values are mean (s.d.). For liver fat median (interquartile range). 
aPsA vs MDF controls. 
bPsA vs MDF controls adjusted for age, sex, and BMI. 
cPsA vs Type 2 diabetes. 
dPsA vs Type 2 diabetes adjusted for age, sex, and BMI. 
ASAT: abdominal subcutaneous adipose tissue; FFMV: fat-free muscle volume; FFMV VCG: virtual control group (VCG) adjusted FFMM; MFI: muscle fat infiltration; VAT: visceral adipose tissue; WMR: weight-to-muscle ratio.

Results

PsA participants were well matched for age and sex with MDF controls but were younger and included a greater proportion of females compared with type 2 diabetes participants (Table 1). There was no statistically significant difference in BMI between PsA, MDF controls and type 2 diabetes. Detailed characteristics of PsA participants including baseline disease activity and cardio-metabolic parameters are outlined in supplementary Table S1, available at Rheumatology online.

PsA participants had a significantly greater VAT volume [mean 5.89 (± s.d. 2.10)] compared with matched MDF controls [4.34 L (± s.d. 1.83)] (P < 0.001), and liver fat percentage [median 8.88% (IQR 4.42–13.18%)] compared with matched MDF controls [3.29% (1.98–7.25%)] (P < 0.001) (Table 1, Fig. 1A). These differences persisted after adjustment for age, sex and BMI. There were no statistically significant differences in VAT, liver fat or MFI between PsA and type 2 diabetes (Table 1, Fig. 1B). PsA participants had lower FFMV and FFMV VCG, and greater weight-to-muscle ratio than MDF controls and type 2 diabetes participants after adjustment (Table 1), indicating lower thigh muscle volume in PsA (Table 1).

The distribution of body-composition predicted propensity for CHD and type 2 diabetes for PsA participants (red) in relation to the complete UK Biobank dataset (grey) is outlined in supplementary Fig. S1, available at Rheumatology online, together with mean disease propensities. PsA participants had 1.27 times higher mean CHD propensity and 1.83 times higher mean type 2 diabetes propensity compared with their matched MDF controls suggestive of a body composition phenotype with stronger association to type 2 diabetes.

Discussion

This is the first study to demonstrate PsA has an adverse body fat distribution compared with healthy controls and which is more in line with type 2 diabetes on MRI with evidence of elevations in VAT and liver fat. Such findings, in turn, predict greater CHD and type 2 diabetes propensity, by 27% and 83% respectively, compared with MDF controls. PsA participants also had lower thigh muscle volume than MDF controls and type 2 diabetes participants.

Previous studies showed greater mean total body fat in PsA (46% ± s.d. 5.7%) compared with healthy controls (43.4% ± 5.5%) (P = 0.04); however, individual fat compartments were not measured [13]. One prior study using CT has reported greater visceral fat in psoriasis compared with age- and sex-matched controls [14], but there was no data on liver fat. Our finding of higher liver fat fraction in PsA fits with increased Non-Alcoholic...
Fatty Liver Disease (NAFLD) prevalence observed in psoriatic disease [15], linked in turn to hepatic insulin resistance [4] and over twice the risk of diabetes compared with those without NAFLD [16].

Of particular note, the reported body composition in PsA is more strongly associated with type 2 diabetes, and to a lesser degree CHD, compared with age, sex and BMI-matched healthy individuals, consistent with observational data [17]. Recent genetic studies have suggested there is a causal link between adverse body fat distribution and cardiometabolic outcomes [18], suggesting that the PsA body composition may be causally linked to such risks.

PsA participants also demonstrated lower thigh fat-free muscle volume (FFMV) compared with MDF controls. Previous work has shown an association between lower FFMV with functional measures of low muscle strength and poor physical performance characteristic of sarcopenia [6]. There are little data on muscle volume in PsA; however, a previous study demonstrated lower skeletal muscle index and higher sarcopenia incidence in PsA compared with controls without inflammatory joint disease [19]. This may relate to decreased physical activity secondary to joint pain and/or underlying chronic inflammation.

Study strengths include that this is the first study to compare detailed body composition parameters between PsA, healthy controls and type 2 diabetes using the gold standard in body composition analysis, MRI. By matching PsA individuals with healthy controls of similar age, sex and BMI, we minimized covariate confounding. Limitations include cross-sectional study design and the modest number of PsA participants. Results should be confirmed in a future study with a larger number of PsA participants including those with varying disease activity and biologic agent use. While IMAPA imaging was conducted in a different centre to UK Biobank, all images were obtained using standardised AMRA protocols and analysed centrally by AMRA. Further, between MR scanner bias and reproducibility has recently been published and has shown that the magnitude of any systematic differences between MR scanners is smaller than the effect sizes observed in this study, lending confidence that the findings we report are genuine and robust [11].

In conclusion, individuals with PsA are metabolically distinct with greater VAT and ectopic liver fat and lower thigh muscle volume than age-, sex- and BMI-matched healthy counterparts, and associated with greater propensity to CHD and type 2 diabetes. Indeed, PsA body fat distribution was more in line with the pattern observed in type 2 diabetes. These novel MRI findings suggest that, as is the case in patients with type 2 diabetes, weight loss should be a core component of PsA disease management to lessen cardiometabolic risk. Large randomized placebo-controlled trials are now needed to prove weight loss improves body composition and outcomes in PsA, as suggested by prior studies [20].

Acknowledgements

L.D.F. and N.S. drafted the initial manuscript. J.L. and O.D.L. performed data analysis and interpretation. L.D.F., N.S., S.S., I.B.M. contributed to study concept/design. R.W., P.H.B., G.R. and A.R. contributed to data acquisition. All authors contributed to critical manuscript revision and final version approval. The authors would like to thank all participants in the IMAPA and UK Biobank.
Biobank studies, and staff at the Glasgow Clinical Research Imaging Facility, Queen Elizabeth University Hospital, Glasgow. The authors also thank Mikael Petersson for statistical support. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. Researchers can apply to use the UK Biobank resource and access the data used. No additional data available.

Funding: This research has been conducted using data from the IMAPA study funded by Celgene (GN16RH008) and the British Heart Foundation (RE/13/5/30177), and data from the UK Biobank resource.

Disclosure statement: L.D.F. was supported by a BHF Centre of Excellence grant (RE/13/5/30177). J.L. and O.D.L. are employees and shareholders in AMRA Medical AB; S.S. reports grants and personal fees from Celgene; I.B.M. reports grants and/or personal fees from Celgene, Abbvie, BMS, Lilly, Novartis, UCB, Janssen, Pfizer, BI and Gilead. N.S. reports grants and/or personal fees from Amgen, Astra Zeneca, Lilly, Novo Nordisk, Pfizer, Sanofi. The other authors have declared no conflicts of interest.

Supplementary data

Supplementary data are available at Rheumatology online.

Data availability statement

Researchers can apply to use the UK Biobank resource and access the data used. No additional data available.

References

1 Love TJ, Zhu Y, Zhang Y et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71:1273–7.
2 Ferguson LD, Brown R, Celis-Morales C et al. Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank. Rheumatology 2019;58:2137–42.
3 Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments. Circulation 2007;116:39–48.
4 Sattar N, Gill JMR. Type 2 diabetes as a disease of ectopic fat. BMC Med 2014;12:123.
5 Linge J, Borga M, West J et al. Body composition profiling in the UK Biobank Imaging Study. Obesity 2018;26:1785–95.
6 Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the definition of sarcopenia in the presence of aging and obesity-initial results from UK Biobank. J Gerontol A 2020;75:1309–16.
7 Ferguson L, Welsh P, Brown R et al. Effect of phosphodiesterase 4 inhibition with apremilast on cardiometabolic outcomes in psoriatic arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) study. Arthritis Rheumatol 2019;71(Suppl 10):2603.
8 Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
9 Scottish Medicines Consortium apremilast (Otezla) PA. https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1053_15_apremilast_Otezla_psoriatic_arthritis (25 March 2020, date last accessed).
10 Sudlow C, Gallacher J, Allen N et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779.
11 Boga M, Ahlgren A, Romu T et al. Reproducibility and repeatability of MRI- based body composition analysis. Magn Reson Med 2020;doi: 10.1002/mrm.28360.
12 Linge J, Whitcher B, Borga M, Dahlqvist Leinhard O. Sub-phenotyping metabolic disorders using body composition: an individualized, nonparametric approach utilizing large data sets. Obesity 2019;27:1190–9.
13 Pedreira PG, Pinheiro MM, Szefnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther 2011;13:R16.
14 Balci A, Balci DD, Yonden Z et al. Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 2010;220:32–7.
15 Ogdie A, Grewal SK, Noe MH et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol 2018;138:760–7.
16 Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41:372–82.
17 Charlton R, Green A, Shaddick G et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology 2019;58:144–8.
18 Lotta LA, Wittermans LBL, Zuber V et al. Association of genetic variants related to glucosefemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. JAMA 2018;320:2553–63.
19 Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W. Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis. Reumatologia 2017;5:215–21.
20 Klingberg E, Bilberg A, Björkman S et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 2019;21:17.